Chinese Stocks Slip as Trump Tariff Deadline Looms

RemeGen signed a license agreement with Vor Biopharma for the development and sale of Telitacicept worldwide except in Greater China, according to a Thursday filing with the Hong Kong bourse.

The license will allow Vor Bio to sell the recombinant B-cell lymphocyte stimulator drug, which is indicated for myasthenia gravis, systemic lupus erythematosus, and rheumatoid arthritis, the filing said.

RemeGen and its subsidiary Yantai Rongpu Investment Partnership will receive up to $125 million in consideration from Vor Bio.

Vor Bio will also issue $80 million in warrants to Yantai Rongpu in exchange for 320 million common shares in Vor Bio or 23% of the enlarged issued share capital, the filing said.

RemeGen will be eligible for an upfront payment of $45 million as well as up to $4.11 billion in milestone payments across several potential indications, and high single-digit to double-digit percentages of actual annual net sales, the filing said.

Shares plunge 17% in Hong Kong and Shanghai during late morning trading on Thursday.

Lu Thai Textile Co booked a profit of 81.0 million yuan from the sale of part of its stake in RemeGen .

The divestment aims to boost liquidity and fund operations, according to a Thursday filing with the Shenzhen bourse.

RemeGen's innovative drug Telitacicept has been granted orphan drug designation by the European Commission for the treatment of myasthenia gravis, according to a Shanghai Stock Exchange filing on Wednesday.

The designation is expected to accelerate the drug's development and potential market entry in the European Union.

Myasthenia gravis is a rare autoimmune disorder characterized by muscle weakness with a global prevalence of about 15-25 cases per 100,000 people, RemeGen said.

RemeGen describes Telitacicept as "the world's first approved innovative BLyS/APRIL dual-targeting fusion protein drug" for myasthenia gravis.